register free | resend password



Ihre Anfrage zu ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
Ihre Benutzername:
e-Mailadresse:
Kommentar / Frage:




All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 75


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.